---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-26-000015"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T03:05:30.393519+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotechnology Q1 loss narrows to $14.7M; cash $143.4M

## Summary
- Net loss of $14.7M vs $16.6M in Q1 2025; operating expenses down 14% YoY to $16.1M.
- Cash, equivalents, and investments total $143.4M as of March 31, 2026.
- Launched Iterative Mapping Early Access Program; Baylor College of Medicine first customer for Tau proteoform assay in NIH-funded cancer study.
- Appointed Amber Faust as VP of Global Sales, a commercial leader from Olink and SomaLogic.

## SEC filing metadata
- accession: 0001808805-26-000015
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/0001808805-26-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/naut-20260428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-26-000015
- JSON: https://secwatch.observer/filing/0001808805-26-000015.json
- Plain text: https://secwatch.observer/filing/0001808805-26-000015.txt

## Key facts
- Earnings Releases
  Nautilus Biotechnology, Inc. reported the quarter ended March 31, 2026 results: net income $14.7 million.
  - Period: the quarter ended March 31, 2026
  - Net income: $14.7 million
  - Result: reported results
  source text: Net loss was $14.7 million for the first quarter of 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/0001808805-26-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.